Jennifer L. Carter is Director at Oncocyte Corp (OCX). They have made 1 open-market trade across 1 company since 2022, most recently 2022-08-16.
CIK 0001806505
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OCX | 20,000 | $64K |
Shares reported on the most recent Form 4, priced at the 2022-08-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OCX | BUY | 2022-08-16 | 2022-08-17 | $0.95 | $10K | -12.2% | -10.1% | -58.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.